Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
Xilio Therapeutics, Inc. (XLO)
Company Research
Source: GlobeNewswire
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. “Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.” Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics, Inc., where she oversaw all corporate legal and compliance matters, including capital markets and licensing transactions, clinical development
Show less
Read more
Impact Snapshot
Event Time:
XLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XLO alerts
High impacting Xilio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
XLO
News
- Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI [Yahoo! Finance]Yahoo! Finance
- Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI GlobeNewswire
- Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer [Yahoo! Finance]Yahoo! Finance
- After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright [Yahoo! Finance]Yahoo! Finance
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
XLO
Sec Filings
- 12/19/24 - Form 4
- 12/19/24 - Form SCHEDULE
- 12/19/24 - Form 8-K
- XLO's page on the SEC website